OTULIN couples WNT signaling to resistance in triple-negative breast cancer

Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphoryl...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Wei Wang [verfasserIn] Zhao-Hui Wu [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2020

Schlagwörter:	dna damage β-catenin linear ubiquitination otulin; drug resistance

Übergeordnetes Werk:	In: Molecular & Cellular Oncology - Taylor & Francis Group, 2022, 7(2020), 6
Übergeordnetes Werk:	volume:7 ; year:2020 ; number:6

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1080/23723556.2020.1825904

Katalog-ID:	DOAJ095103821

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ095103821
003	DE-627
005	20240413091522.0
007	cr uuu---uuuuu
008	240413s2020 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1080/23723556.2020.1825904 \|2 doi
035			\|a (DE-627)DOAJ095103821
035			\|a (DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Wei Wang \|e verfasserin \|4 aut
245	1	0	\|a OTULIN couples WNT signaling to resistance in triple-negative breast cancer
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer.
650		4	\|a dna damage
650		4	\|a β-catenin
650		4	\|a linear ubiquitination
650		4	\|a otulin; drug resistance
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Zhao-Hui Wu \|e verfasserin \|4 aut
773	0	8	\|i In \|t Molecular & Cellular Oncology \|d Taylor & Francis Group, 2022 \|g 7(2020), 6 \|w (DE-627)835890988 \|w (DE-600)2835425-4 \|x 23723556 \|7 nnns
773	1	8	\|g volume:7 \|g year:2020 \|g number:6
856	4	0	\|u https://doi.org/10.1080/23723556.2020.1825904 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06 \|z kostenfrei
856	4	0	\|u http://dx.doi.org/10.1080/23723556.2020.1825904 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2372-3556 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 7 \|j 2020 \|e 6

Indexfelder

author_variant	w w ww z h w zhw
matchkey_str	article:23723556:2020----::tlnopewtinlntrssacitilng
hierarchy_sort_str	2020
callnumber-subject-code	RC
publishDate	2020
allfields	10.1080/23723556.2020.1825904 doi (DE-627)DOAJ095103821 (DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06 DE-627 ger DE-627 rakwb eng RC254-282 Wei Wang verfasserin aut OTULIN couples WNT signaling to resistance in triple-negative breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer. dna damage β-catenin linear ubiquitination otulin; drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens Zhao-Hui Wu verfasserin aut In Molecular & Cellular Oncology Taylor & Francis Group, 2022 7(2020), 6 (DE-627)835890988 (DE-600)2835425-4 23723556 nnns volume:7 year:2020 number:6 https://doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06 kostenfrei http://dx.doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/toc/2372-3556 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2014 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 6
spelling	10.1080/23723556.2020.1825904 doi (DE-627)DOAJ095103821 (DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06 DE-627 ger DE-627 rakwb eng RC254-282 Wei Wang verfasserin aut OTULIN couples WNT signaling to resistance in triple-negative breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer. dna damage β-catenin linear ubiquitination otulin; drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens Zhao-Hui Wu verfasserin aut In Molecular & Cellular Oncology Taylor & Francis Group, 2022 7(2020), 6 (DE-627)835890988 (DE-600)2835425-4 23723556 nnns volume:7 year:2020 number:6 https://doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06 kostenfrei http://dx.doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/toc/2372-3556 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2014 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 6
allfields_unstemmed	10.1080/23723556.2020.1825904 doi (DE-627)DOAJ095103821 (DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06 DE-627 ger DE-627 rakwb eng RC254-282 Wei Wang verfasserin aut OTULIN couples WNT signaling to resistance in triple-negative breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer. dna damage β-catenin linear ubiquitination otulin; drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens Zhao-Hui Wu verfasserin aut In Molecular & Cellular Oncology Taylor & Francis Group, 2022 7(2020), 6 (DE-627)835890988 (DE-600)2835425-4 23723556 nnns volume:7 year:2020 number:6 https://doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06 kostenfrei http://dx.doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/toc/2372-3556 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2014 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 6
allfieldsGer	10.1080/23723556.2020.1825904 doi (DE-627)DOAJ095103821 (DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06 DE-627 ger DE-627 rakwb eng RC254-282 Wei Wang verfasserin aut OTULIN couples WNT signaling to resistance in triple-negative breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer. dna damage β-catenin linear ubiquitination otulin; drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens Zhao-Hui Wu verfasserin aut In Molecular & Cellular Oncology Taylor & Francis Group, 2022 7(2020), 6 (DE-627)835890988 (DE-600)2835425-4 23723556 nnns volume:7 year:2020 number:6 https://doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06 kostenfrei http://dx.doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/toc/2372-3556 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2014 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 6
allfieldsSound	10.1080/23723556.2020.1825904 doi (DE-627)DOAJ095103821 (DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06 DE-627 ger DE-627 rakwb eng RC254-282 Wei Wang verfasserin aut OTULIN couples WNT signaling to resistance in triple-negative breast cancer 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer. dna damage β-catenin linear ubiquitination otulin; drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens Zhao-Hui Wu verfasserin aut In Molecular & Cellular Oncology Taylor & Francis Group, 2022 7(2020), 6 (DE-627)835890988 (DE-600)2835425-4 23723556 nnns volume:7 year:2020 number:6 https://doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06 kostenfrei http://dx.doi.org/10.1080/23723556.2020.1825904 kostenfrei https://doaj.org/toc/2372-3556 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2014 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 6
language	English
source	In Molecular & Cellular Oncology 7(2020), 6 volume:7 year:2020 number:6
sourceStr	In Molecular & Cellular Oncology 7(2020), 6 volume:7 year:2020 number:6
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	dna damage β-catenin linear ubiquitination otulin; drug resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Molecular & Cellular Oncology
authorswithroles_txt_mv	Wei Wang @@aut@@ Zhao-Hui Wu @@aut@@
publishDateDaySort_date	2020-01-01T00:00:00Z
hierarchy_top_id	835890988
id	DOAJ095103821
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ095103821</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413091522.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1080/23723556.2020.1825904</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ095103821</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Wei Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">OTULIN couples WNT signaling to resistance in triple-negative breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna damage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">β-catenin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">linear ubiquitination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">otulin; drug resistance</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhao-Hui Wu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Molecular & Cellular Oncology</subfield><subfield code="d">Taylor & Francis Group, 2022</subfield><subfield code="g">7(2020), 6</subfield><subfield code="w">(DE-627)835890988</subfield><subfield code="w">(DE-600)2835425-4</subfield><subfield code="x">23723556</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1080/23723556.2020.1825904</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1080/23723556.2020.1825904</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2372-3556</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Wei Wang
spellingShingle	Wei Wang misc RC254-282 misc dna damage misc β-catenin misc linear ubiquitination misc otulin; drug resistance misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens OTULIN couples WNT signaling to resistance in triple-negative breast cancer
authorStr	Wei Wang
ppnlink_with_tag_str_mv	@@773@@(DE-627)835890988
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	23723556
topic_title	RC254-282 OTULIN couples WNT signaling to resistance in triple-negative breast cancer dna damage β-catenin linear ubiquitination otulin; drug resistance
topic	misc RC254-282 misc dna damage misc β-catenin misc linear ubiquitination misc otulin; drug resistance misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc dna damage misc β-catenin misc linear ubiquitination misc otulin; drug resistance misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc dna damage misc β-catenin misc linear ubiquitination misc otulin; drug resistance misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Molecular & Cellular Oncology
hierarchy_parent_id	835890988
hierarchy_top_title	Molecular & Cellular Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)835890988 (DE-600)2835425-4
title	OTULIN couples WNT signaling to resistance in triple-negative breast cancer
ctrlnum	(DE-627)DOAJ095103821 (DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06
title_full	OTULIN couples WNT signaling to resistance in triple-negative breast cancer
author_sort	Wei Wang
journal	Molecular & Cellular Oncology
journalStr	Molecular & Cellular Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2020
contenttype_str_mv	txt
author_browse	Wei Wang Zhao-Hui Wu
container_volume	7
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Wei Wang
doi_str_mv	10.1080/23723556.2020.1825904
author2-role	verfasserin
title_sort	otulin couples wnt signaling to resistance in triple-negative breast cancer
callnumber	RC254-282
title_auth	OTULIN couples WNT signaling to resistance in triple-negative breast cancer
abstract	Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer.
abstractGer	Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer.
abstract_unstemmed	Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2014 GBV_ILN_2190 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	6
title_short	OTULIN couples WNT signaling to resistance in triple-negative breast cancer
url	https://doi.org/10.1080/23723556.2020.1825904 https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06 http://dx.doi.org/10.1080/23723556.2020.1825904 https://doaj.org/toc/2372-3556
remote_bool	true
author2	Zhao-Hui Wu
author2Str	Zhao-Hui Wu
ppnlink	835890988
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1080/23723556.2020.1825904
callnumber-a	RC254-282
up_date	2024-07-04T01:54:50.686Z
_version_	1803611632501260288
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ095103821</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413091522.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240413s2020 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1080/23723556.2020.1825904</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ095103821</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ81c271b1839149c3a03e35b12feb1a06</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Wei Wang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">OTULIN couples WNT signaling to resistance in triple-negative breast cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oncogenic Wnt/β-catenin activation promotes cancer development and drug resistance to cancer treatments. We recently revealed an underlying mechanism linking linear ubiquitination with Wnt/β-catenin activation upon genotoxic treatments. We showed that ABL1 (ABL proto-oncogene 1)-dependent phosphorylation of OTULIN (OTU deubiquitinase with linear linkage specificity) upon DNA damage drives β-catenin activation which promotes drug resistance in triple-negative breast cancer.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dna damage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">β-catenin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">linear ubiquitination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">otulin; drug resistance</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhao-Hui Wu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Molecular & Cellular Oncology</subfield><subfield code="d">Taylor & Francis Group, 2022</subfield><subfield code="g">7(2020), 6</subfield><subfield code="w">(DE-627)835890988</subfield><subfield code="w">(DE-600)2835425-4</subfield><subfield code="x">23723556</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1080/23723556.2020.1825904</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/81c271b1839149c3a03e35b12feb1a06</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1080/23723556.2020.1825904</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2372-3556</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2020</subfield><subfield code="e">6</subfield></datafield></record></collection>
score	7.39933

Nicht das Richtige dabei?

Schreiben Sie uns!

OTULIN couples WNT signaling to resistance in triple-negative breast cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?